Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?

#PrEP #PrEP #FDA #GileadSciences #HIV #USA #preexposureprophylaxis #PrEP #HIVpreexposureprophylaxis #Yeztugo #phase3trials #PURPOSE1 #PURPOSE2 #HIVprevention #Truvada #PrEPmarket #emtricitabinetenofoviralafenamide #PrEPusers #HIVfunding #Prep4All
pharmaphorum.com/news/gileads...